StartupHistory

An open directory of startups through time

Public records · dated sources
Free to read. Free to reuse.

Company records / cgoncology.com

CG Oncology

CG Oncology (cgoncology.com): 1 change recorded in its website history since August 2020. Homepage last checked 6 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

  1. InvestorsBetween and

    Now shows investor logos: acorn bioventures, ally bridge group, decheng capital, kissei pharmaceutical, lepu medical, longitude capital, malin corporation, ori capital and 2 more.

    Observed on the company’s website; business claims are not independently verified.

    earlier archived pagelater archived pageLink to observation

First recorded website

Observed 11 August 2020

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers.

Cold Genesys is a clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.

archived pageLink to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

  1. January 2024 – January 2025 · 3 captures · latest observed messagingWe are focused on developing bladder-sparing oncolytic immunotherapies for patients afflicted with bladder cancer.

    CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer.

    This wording observed 11 January 2025.

    archived page
    Inspect 3 captures in this group
    • 4 January 2024 · Bladder cancer | Oncolytic immunotherapy | CG0070 | CG Oncology - CG Oncology | archived page
    • 15 July 2024 · We are focused on developing bladder-sparing oncolytic immunotherapies for patients afflicted with bladder cancer. archived page
    • 11 January 2025 · We are focused on developing bladder-sparing oncolytic immunotherapies for patients afflicted with bladder cancer. archived page
  2. August 2020 – October 2022 · 4 capturesDeveloping the next evolution of oncolytic immunotherapy for patients with advanced cancers.

    CG Oncology is a clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies.

    This wording observed 12 October 2022.

    archived page
    Inspect 4 captures in this group
    • 11 August 2020 · Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers. archived page
    • 25 January 2021 · Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers. archived page
    • 19 January 2022 · Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers. archived page
    • 12 October 2022 · Developing the next evolution of oncolytic immunotherapy for patients with advanced cancers. archived page

Cite this record

StartupHistory, “CG Oncology” company record, https://startuphistory.org/c/cgoncology.com

Machine-readable: /c/cgoncology.com.json. How changes are found: method.